Home » Newsletters » BioWorld Science

BioWorld Science

June 19, 2007

View Archived Issues

Prous Sciences publishes new Integrity Disease Briefing on myasthenia gravis

Novel anticancer agents disclosed in recent patents

Recent patents disclose novel therapeutic agents for inflammatory disorders

Recent Merck patent imparts novel antiobesity agents

Boehringer Ingelheim to evaluate Aptivus in diverse patient population

Novel treatment options for autoimmune disorders described in recent patents

Inhibition of aP2: a novel therapeutic strategy in treating diabetes and atherosclerosis

Apo2L/TRAIL in patients with advanced tumors

NeuroSearch's latest pipeline progress and status

Phase III findings show benefit of AMG-0001 in critical limb ischemia

Canadian approval for Elaprase for Hunter's syndrome

Enrollment completed in phase I study of SL-017 in actinic keratosis

NicOx takes precautionary measures on NCX-4016 program

Novo Nordisk studies GlycoPEGylated factor VIIa in phase I trial

Highlights from the Alzheimer's Association International Conference on Prevention of Dementia

Meda acquires sotirimod from 3M

Diamyd Medical invalidates diabetes study

Novel multi-target tyrosine kinase inhibitor profiled at LEO

Solvay seeks new indications for AndroGel

Japanese launch for Abilify Tablet 12 mg

Nuvigil approved to treat excessive sleepiness

NuvaRing approved in additional E.U. countries

First E.U. launches for Advagraf in U.K. and Germany

Bazedoxifene/conjugated estrogens improves BMD in postmenopausal women

Japanese launch planned for Pletaal Powder 20%

Expanded access program opens for Kuvan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...